If you have been reading about research chemical and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
== Functions == The various functions of the liver are carried out by the liver cells or hepatocytes. The liver is thought to be responsible for up to 500 separate functions, usually in combination with other systems and organs. Currently, no artificial organ or device is capable of reproducing all the functions of the liver. Some functions can be carried out by liver dialysis, an experimental treatment for liver failure. The liver also accounts for about 20% of resting total body oxygen consumption.
ideal gas law Also general gas equation. The equation of state of a hypothetical ideal gas, which states that the volume of such a gas is proportional to the amount of gas and its Kelvin temperature, and inversely proportional to its pressure. The ideal gas law combines Boyle's law, Charles's law, Gay-Lussac's law, and Avogadro's law into a single equation, conventionally formulated as
25 June – Astronomers report the discovery and confirmation of two unusually low-density exoplanets, TOI-791 b and TOI-791 c, orbiting the star TOI-791 about 1,113 light-years from Earth. Detected using NASA's Transiting Exoplanet Survey Satellite, the Jupiter-sized "super-puff" planets have densities of 0.038 and 0.047 g/cm3, respectively, making them among the lowest-density giant planets known and the largest planets yet found with densities below 0.05 g/cm3. 29 June – Palaeontologists identify a fossil vertebra collected on James Ross Island in 1985 as the earliest-known dinosaur bone collected in Antarctica. The specimen, stored for 40 years in the British Antarctic Survey collections, is confirmed to be a tail bone from a titanosaur, a group of long-necked sauropod dinosaurs. The animal is estimated to have lived about 82 million years ago, during the Late Cretaceous, when Antarctica was covered in forest. 30 June – Astronomers report a revised orbit and mass for the nearby habitable zone super-Earth GJ 3378 b. Combining radial velocity data from the Habitable-zone Planet Finder, NEID, CARMENES and SPIRou spectrometers, the team finds that the planet has an orbital period of 21.45 days and a minimum mass of 2.3 Earth masses, rather than earlier estimates of 24.73 days and 5.26 Earth masses. The revision leaves the planet within the conservative liquid-water habitable zone of its red dwarf host star, increases the likelihood that it has a terrestrial composition, and suggests that it may have retained an atmosphere despite high X-ray and ultraviolet exposure.
Sources: en.wikipedia.org
The post-Arbenz government—a military junta headed by Carlos Castillo Armas—repealed a progressive land reform law, returned nationalized property belonging to the United Fruit Company, set up a National Committee of Defense Against Communism, and decreed a Preventive Penal Law Against Communism at the request of the United States. The non-aligned Indonesian government of Sukarno was faced with a major threat to its legitimacy beginning in 1956 when several regional commanders began to demand autonomy from Jakarta. After mediation failed, Sukarno took action to remove the dissident commanders. In February 1958, dissident military commanders in Central Sumatra (Colonel Ahmad Husein) and North Sulawesi (Colonel Ventje Sumual) declared the Revolutionary Government of the Republic of Indonesia-Permesta Movement aimed at overthrowing the Sukarno regime. They were joined by many civilian politicians from the Masyumi Party, such as Sjafruddin Prawiranegara, who were opposed to the growing influence of the communist Partai Komunis Indonesia. Due to their anti-communist rhetoric, the rebels received arms, funding, and other covert aid from the CIA until Allen Lawrence Pope, an American pilot, was shot down after a bombing raid on government-held Ambon in April 1958. The central government responded by launching airborne and seaborne military invasions of rebel strongholds at Padang and Manado. By the end of 1958, the rebels were militarily defeated, and the last remaining rebel guerilla bands surrendered by August 1961.
As of 2018, some retailers had begun experimenting with the use of blue light bulbs in bathrooms in order to deter addicts from using such spaces to inject opiates. Blue lights are said to make finding veins to inject more difficult. However, a 2013 study has found that the use of blue lights are unlikely to deter drugs users from injecting in public washrooms and may increase drug use-related harm.
MS is not considered a hereditary disease, but over 200 genetic variants have been shown to increase its risk. The probability of developing MS is higher in relatives of an affected person, with a greater risk among those more closely related. An identical twin of an affected individual has a 30% chance of developing MS, 5% for a nonidentical twin, 2.5% for a sibling, and an even lower chance for a half-sibling. MS is also more common in some ethnic groups than others. Specific genes linked with MS include differences in the human leukocyte antigen (HLA) system—a group of genes on chromosome 6 that serves as the major histocompatibility complex (MHC). The MHC is involved in how antigens are presented and how abundant different types of T cells are. The MHC allele (genetic variant) HLA-DRB1*15:01 which is present in 30% of the U.S. and Northern European population, produces the strongest association with higher risk of MS. Other allelles related to MHC exhibit a protective effect. The contribution of HLA variants to MS susceptibility has been known since the 1980s, and it has also been implicated in the development of other autoimmune diseases. Genetic variants in autoimmune diseases are typically linked to T cells, but in MS (and lupus), many are linked to B cells too. In general, MS is associated more closely to autoimmune diseases than to other neurodegenerative diseases.
Sources: en.wikipedia.org
Nussio, Enzo; Ugarriza, Juan E. (2021). "Why Rebels Stop Fighting: Organizational Decline and Desertion in Colombia's Insurgency". International Security. 45 (4): 167–203. doi:10.1162/isec_a_00406. hdl:20.500.11850/480000. ISSN 0162-2889. Sherman, John W. "Political Violence in Colombia: Dirty Wars Since 1977." History Compass (Sep 2015) 13#9 pp 454–465. Cirlig, Carmen-Cristina. "Colombia: new momentum for peace?" (PDF). Library Briefing. Library of the European Parliament. Retrieved July 15, 2013. Azcarate, Camilo A. (March 1999). "Psychosocial Dynamics of the Armed Conflict in Colombia". Online Journal of Peace and Conflict Resolution. Archived from the original on January 6, 2003. James Petras (July 2, 1988). "Neglected Dimensions of Violence". Economic and Political Weekly. 23 (27): 1367. JSTOR 4378701. Elizabeth F. Schwartz (Winter 1995–1996). "Getting Away with Murder: Social Cleansing in Colombia and the Role of the United States". The University of Miami Inter-American Law Review. 27 (2): 381–420. John Lindsay-Poland (January–February 2010). "Retreat to Colombia: The Pentagon Adapts Its Latin America Strategy". NACLA Report on the Americas. Government/NGO reports
A review of the UKPDS, Action to Control Cardiovascular Risk in Diabetes (ACCORD), Advance and Veterans Affairs Diabetes Trials (VADT) estimated that the risks of the main complications of diabetes (diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, and macrovascular disease) decreased by about 3% for every 1 mmol/mol decrease in HbA1c. However, a trial by ACCORD designed specifically to determine whether reducing HbA1c below 42 mmol/mol (6.0 DCCT %) using increased amounts of medication would reduce the rate of cardiovascular events found higher mortality with this intensive therapy, so much so that the trial was terminated 17 months early. Practitioners must consider patients' health, their risk of hypoglycemia, and their specific health risks when setting a target HbA1c level. Because patients are responsible for averting or responding to their own hypoglycemic episodes, their input and the doctors' assessments of the patients' self-care skills are also important. Persistent elevations in blood sugar (and, therefore, HbA1c) increase the risk of long-term vascular complications of diabetes, such as coronary disease, heart attack, stroke, heart failure, kidney failure, blindness, erectile dysfunction, neuropathy (loss of sensation, especially in the feet), gangrene, and gastroparesis (slowed emptying of the stomach). Poor blood glucose control also increases the risk of short-term complications of surgery, such as poor wound healing.
== Business, finance, and economics == Safety improvement plan, a plan for improving safety Sales incentive plan, a type of employee incentive program Securities information processor, the part of public infrastructure for disseminating market data in the United States Share Incentive Plan, a UK government approved employee plan Systematic investment plan, an investment strategy
== External links == GeneReviews/NCBI/NIH/UW entry on Ehlers-Danlos Syndrome, Hypermobility Type This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.